[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adc Therapeutics Sa (ADCT)

Adc Therapeutics Sa (ADCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,735
  • Shares Outstanding, K 127,191
  • Annual Sales, $ 81,360 K
  • Annual Income, $ -142,620 K
  • EBIT $ -118 M
  • EBITDA $ -116 M
  • 60-Month Beta 1.77
  • Price/Sales 1.59
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 353.25% (-167.06%)
  • Historical Volatility 256.73%
  • IV Percentile 59%
  • IV Rank 36.44%
  • IV High 896.55% on 06/08/26
  • IV Low 41.82% on 02/18/26
  • Expected Move (DTE 17) 0.0425 (4.13%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 124
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 3,602
  • Open Int (30-Day) 4,364
  • Expected Range 0.9875 to 1.0725

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.19
  • Number of Estimates 1
  • High Estimate $-0.19
  • Low Estimate $-0.19
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) +62.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7796 +32.12%
on 06/08/26
3.4900 -70.49%
on 06/01/26
-2.3700 (-69.71%)
since 05/29/26
3-Month
0.7796 +32.12%
on 06/08/26
4.8200 -78.63%
on 04/16/26
-2.6700 (-72.16%)
since 03/27/26
52-Week
0.7796 +32.12%
on 06/08/26
4.9800 -79.32%
on 03/11/26
-1.6800 (-61.99%)
since 06/27/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact...

ADCT : 1.0300 (+0.98%)
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility

ADCT : 1.0300 (+0.98%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK , June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT).  Such investors are advised to...

ADCT : 1.0300 (+0.98%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK , June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to...

ADCT : 1.0300 (+0.98%)
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end

ADCT : 1.0300 (+0.98%)
ADC Therapeutics Reports Monday With Single-Product Dependency and No Clear Path to Profitability

Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...

ADCT : 1.0300 (+0.98%)
ADC Therapeutics Reports Monday With Single-Product Dependency and No Clear Path to Profitability

Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...

ADCT : 1.0300 (+0.98%)
ADC Therapeutics Reports Monday With Single-Product Dependency and No Clear Path to Profitability

Barchart Research What to Expect from ADCT Earnings ADCT Generated May 1, 2026 Current Price $3.83 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 10.96% ADC Therapeutics Reports Monday With...

ADCT : 1.0300 (+0.98%)
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland , May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 1.0300 (+0.98%)
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

LAUSANNE, Switzerland , April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 1.0300 (+0.98%)

Business Summary

ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.

See More

Key Turning Points

3rd Resistance Point 1.1367
2nd Resistance Point 1.1033
1st Resistance Point 1.0667
Last Price 1.0300
1st Support Level 0.9967
2nd Support Level 0.9633
3rd Support Level 0.9267

See More

52-Week High 4.9800
Fibonacci 61.8% 3.3754
Fibonacci 50% 2.8798
Fibonacci 38.2% 2.3842
Last Price 1.0300
52-Week Low 0.7796

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.